In that context, very recently it was reported that hospitalized COVID-19 patients receiving a single subcutaneous injection of the PCSK9-mAb evolocumab exhibited reduced death or need for intubation, as well as decreased inflammatory cytokine IL-6 levels in severe COVID-19 cases [92]. This evidence concerns the gene PCSK9 and COVID-19.